+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease



Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease



Therapeutic Apheresis and Dialysis 15(2): 125-128



Several abnormalities of the cardiovascular system are observed in most cases of chronic kidney disease (CKD). Mechanisms underlying these abnormalities are complicated, and several factors contribute to their pathogenesis. Of these factors, oxidative stress and uremic toxins are considered to play key roles in the progression of cardiovascular disease (CVD) in CKD. Oxidative stress increases significantly in CKD and accelerates proteinuria and renal dysfunction. In addition, oxidative stress has been reported to induce cardiac hypertrophy and fibrosis. Indoxyl sulfate, a uremic toxin, has recently been suggested to play a crucial role in the development of CVD. Recent in vitro data suggest that indoxyl sulfate increases oxidative stress. Some reports have shown that AST-120, which is an oral charcoal adsorbent, can reduce oxidative stress by lowering serum indoxyl sulfate levels. Recently, we have also demonstrated that indoxyl sulfate is associated with the production of oxidative stress, and that increased oxidative stress is significantly correlated with cardiac hypertrophy and fibrosis. Furthermore, results of our basic and clinical studies suggested that AST-120 can prevent progression of cardiac hypertrophy by reducing oxidative stress in CKD. Thus, one of the main targets of the management of CKD and CVD is the control of oxidative stress and uremic toxins, such as indoxyl sulfate.

(PDF emailed within 0-6 h: $19.90)

Accession: 055609452

Download citation: RISBibTeXText

PMID: 21426501

DOI: 10.1111/j.1744-9987.2010.00883.x


Related references

Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Therapeutic Apheresis and Dialysis 15(2): 120-124, 2011

Indoxyl sulfate-lowering capacity of oral sorbents affects the prognosis of kidney function and oxidative stress in chronic kidney disease. Journal of Renal Nutrition 17(1): 48-52, 2007

Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clinical Journal of the American Society of Nephrology 6(1): 30-39, 2011

Indoxyl Sulfate Affects Glial Function Increasing Oxidative Stress and Neuroinflammation in Chronic Kidney Disease: Interaction between Astrocytes and Microglia. Frontiers in Pharmacology 8: 370, 2017

Indoxyl sulfate: a candidate target for the prevention and treatment of cardiovascular disease in chronic kidney disease. Current Drug Targets 16(4): 366-372, 2016

Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease. Archives of Medical Research 43(6): 451-456, 2013

Serum indoxyl sulfate is a useful predictor for progression of chronic kidney disease. Rinsho Byori. Japanese Journal of Clinical Pathology 58(5): 448-453, 2010

Role of uremic toxin indoxyl sulfate in the progression of cardiovascular disease. Life Sciences 185: 23-29, 2017

Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease. Bmc Nephrology 18(1): 35, 2017

Indoxyl Sulfate: A Novel Cardiovascular Risk Factor in Chronic Kidney Disease. Journal of the American Heart Association 6(2), 2017

Plasma indoxyl sulfate concentration predicts progression of chronic kidney disease in dogs and cats. Veterinary Journal 232: 33-39, 2018

Plasma indoxyl sulfate concentration predicts progression of chronic kidney disease in dogs and cats. Veterinary Journal 232: 33-39, 2018

Serum indoxyl sulfate predicts adverse cardiovascular events in patients with chronic kidney disease. Journal of the Formosan Medical Association 2019, 2019

Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease. Clinical and Experimental Nephrology 18(2): 265-268, 2014

Role of oxidative stress on chronic kidney disease progression. Acta Medica Indonesiana 46(3): 244-252, 2015